Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2016 1
2017 2
2018 1
2019 1
2021 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.
Codarri Deak L, Nicolini V, Hashimoto M, Karagianni M, Schwalie PC, Lauener L, Varypataki EM, Richard M, Bommer E, Sam J, Joller S, Perro M, Cremasco F, Kunz L, Yanguez E, Hüsser T, Schlenker R, Mariani M, Tosevski V, Herter S, Bacac M, Waldhauer I, Colombetti S, Gueripel X, Wullschleger S, Tichet M, Hanahan D, Kissick HT, Leclair S, Freimoser-Grundschober A, Seeber S, Teichgräber V, Ahmed R, Klein C, Umaña P. Codarri Deak L, et al. Among authors: schlenker r. Nature. 2022 Oct;610(7930):161-172. doi: 10.1038/s41586-022-05192-0. Epub 2022 Sep 28. Nature. 2022. PMID: 36171284 Free PMC article.
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P. Bacac M, et al. Among authors: schlenker r. Clin Cancer Res. 2018 Oct 1;24(19):4785-4797. doi: 10.1158/1078-0432.CCR-18-0455. Epub 2018 May 1. Clin Cancer Res. 2018. PMID: 29716920
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, Diggelmann S, Challier J, Mössner E, Hosse RJ, Hofer T, Brünker P, Joseph C, Benz J, Ringler P, Stahlberg H, Lauer M, Perro M, Chen S, Küttel C, Bhavani Mohan PL, Nicolini V, Birk MC, Ongaro A, Prince C, Gianotti R, Dugan G, Whitlow CT, Solingapuram Sai KK, Caudell DL, Burgos-Rodriguez AG, Cline JM, Hettich M, Ceppi M, Giusti AM, Crameri F, Driessen W, Morcos PN, Freimoser-Grundschober A, Levitsky V, Amann M, Grau-Richards S, von Hirschheydt T, Tournaviti S, Mølhøj M, Fauti T, Heinzelmann-Schwarz V, Teichgräber V, Colombetti S, Bacac M, Zippelius A, Klein C, Umaña P. Claus C, et al. Among authors: schlenker r. Sci Transl Med. 2019 Jun 12;11(496):eaav5989. doi: 10.1126/scitranslmed.aav5989. Sci Transl Med. 2019. PMID: 31189721 Free PMC article.
Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses.
Sia J, Hagekyriakou J, Chindris I, Albarakati H, Leong T, Schlenker R, Keam SP, Williams SG, Neeson PJ, Johnstone RW, Haynes NM. Sia J, et al. Among authors: schlenker r. Int J Radiat Oncol Biol Phys. 2021 Oct 1;111(2):502-514. doi: 10.1016/j.ijrobp.2021.05.014. Epub 2021 May 21. Int J Radiat Oncol Biol Phys. 2021. PMID: 34023423 Free article.
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents.
Herter S, Morra L, Schlenker R, Sulcova J, Fahrni L, Waldhauer I, Lehmann S, Reisländer T, Agarkova I, Kelm JM, Klein C, Umana P, Bacac M. Herter S, et al. Among authors: schlenker r. Cancer Immunol Immunother. 2017 Jan;66(1):129-140. doi: 10.1007/s00262-016-1927-1. Epub 2016 Nov 17. Cancer Immunol Immunother. 2017. PMID: 27858101 Free PMC article.
Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma.
Schlenker R, Schwalie PC, Dettling S, Huesser T, Irmisch A, Mariani M, Martínez Gómez JM, Ribeiro A, Limani F, Herter S, Yángüez E, Hoves S, Somandin J, Siebourg-Polster J, Kam-Thong T, de Matos IG, Umana P, Dummer R, Levesque MP, Bacac M. Schlenker R, et al. Med. 2024 Apr 4:S2666-6340(24)00127-2. doi: 10.1016/j.medj.2024.03.015. Online ahead of print. Med. 2024. PMID: 38593812 Free article.
Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
Schlenker R, Olguín-Contreras LF, Leisegang M, Schnappinger J, Disovic A, Rühland S, Nelson PJ, Leonhardt H, Harz H, Wilde S, Schendel DJ, Uckert W, Willimsky G, Noessner E. Schlenker R, et al. Cancer Res. 2017 Jul 1;77(13):3577-3590. doi: 10.1158/0008-5472.CAN-16-1922. Epub 2017 May 22. Cancer Res. 2017. PMID: 28533272